Dzordzo Y. Violation of serum albumin binding function in patients with hypertensive disease associated with nonalcoholic steatohepatitis and type 2 diabetes

The thesis adduces a theoretical generalization and a new practical solution to a current scientific task, consisting in clarifying the significance of serum albumin binding function (SABF) in the pathogenesis of hypertensive disease (HD) without concomitant pathology and in its comorbid course with one of the manifestations of non-alcoholic fatty liver disease – nonalcoholic steatohepatitis (NASH) and diabetes mellitus (DM) type 2, as well as its relationships with the content of protein fractions, the activity of liver enzymes, indicators of endogenous intoxication, lipid and carbohydrate metabolism, and clinical-pathogenetic rationale of the effectiveness of the drug “Antral” in order to correct the detected changes. It was established that concomitant NASH and type 2 diabetes in HD lead to a decrease in SABF, changes in protein metabolism due to a decrease in the liver’s protein-synthesizing capacity, and also increase cholesterol metabolism disorders and endogenous intoxication. All changes in the combination of HD with NASH and with NASH and type 2 diabetes were more pronounced compared to HD without significant comorbidities. It was found that SABF in HD with concomitant NASH and NASH and type 2 diabetes depends on the level of total protein and albumin content. It was also established the presence of an inverse correlation between SABF and markers of the functional state of the liver, as well as indicators of endogenous intoxication. It was found that the use of “Antral” contributes to the recovery of SABF under the conditions of HD with concomitant NASH and with NASH and type 2 diabetes, as well as reducing the phenomena of endogenous intoxication, improving the functional state of the liver and cholesterol metabolism.